Thus, epitope downregulation is not a common driver of acquired resistance to TROP2 or HER2 ADCs, and second-line ADC therapies may benefit from distinct payloads.<h4>Significance</h4>ADCs target tumor-associated antigens, followed by internalization and release of drug payloads. The gene discussed is TACSTD2; the disease is neoplasm.